Edwards Lifesciences to Expand Its Manufacturing and R&D Capability

SALT LAKE CITY, UT, Oct 08 (MARKET WIRE) --
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the
science of heart valves and hemodynamic monitoring, announced today that
in anticipation of future growth, the company will be developing a new
state-of-the-art manufacturing facility in Draper, Utah, which will
enable it to significantly expand its manufacturing and R&D capability.

"Our new facility will allow us to evolve our world class operations to
support Edwards' long-term global product supply strategy," said Paul C.
Redmond, Edwards' corporate vice president, Global Corporate Operations.
"We are very grateful to the Governor's Office of Economic Development in
Utah and the Draper City Council for their extraordinary efforts in
working with us to ensure our success in creating a stronger and more
customer-focused company, poised for even more growth in the future."

Edwards has accepted incentives from the State of Utah totaling
approximately $11.5 million based on the current 228 jobs being retained
and more than 1,000 projected new jobs in manufacturing, business and
engineering expected to be created in the state during the life of the
15-year incentive period. The company also accepted an incentive from the
City of Draper for approximately $3 million based on capital investments
and employment rates over a seven-year incentive period.

As the first step of its planned expansion, the company will transfer
manufacturing of its market-leading cannula and embolic protection devices
utilized by cardiac surgeons during open-heart surgery from its existing
Midvale, Utah facility to the new facility in Draper in the first half of
2010.

About Edwards Lifesciences

Edwards Lifesciences is the global leader in the science of heart valves
and hemodynamic monitoring, with more than five decades of experience in
partnering with clinicians to develop life-saving innovations.
Headquartered in Irvine, Calif., Edwards treats advanced cardiovascular
disease with its market-leading heart valve therapies, and critical care
and vascular technologies, which are sold in approximately 100 countries.
The company's global brands include Carpentier-Edwards, Cosgrove-Edwards,
Edwards SAPIEN, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz.
Additional company information can be found at http://www.edwards.com.

This news release includes forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. These forward-looking statements can
sometimes be identified by the use of words such as "may," "will,"
"should," "anticipate," "believe," "plan," "project," "estimate,"
"expect," "intend," or other similar expressions and include, but are not
limited to, development plans for the company's new facility in Draper,
Utah, and the company's growth and employment projections.
Forward-looking statements are based on estimates and assumptions made by
management of the company and are believed to be reasonable, though they
are inherently uncertain and difficult to predict. Our forward-looking
statements speak only as of the date on which they are made and we do not
undertake any obligation to update any forward-looking statement to
reflect events or circumstances after the date of the statement.

Forward-looking statements involve risks and uncertainties that could
cause actual results or experience to differ materially from that
expressed or implied by the forward-looking statements. Factors that
could cause actual results or experience to differ materially from that
expressed or implied by the forward-looking statements include those and
other risks detailed in the company's filings with the Securities and
Exchange Commission including its Annual Report on Form 10-K for the year
ended December 31, 2008.

Edwards is a trademark of Edwards Lifesciences Corporation. Edwards
Lifesciences, the stylized E logo, Carpentier-Edwards, Cosgrove-Edwards,
FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz are trademarks of Edwards
Lifesciences Corporation and are registered in the United States Patent
and Trademark Office.

Media Contact:
Amanda Fowler
949-250-5070

Investor Contact:
David K. Erickson
949-250-6826

Copyright 2009, Market Wire, All rights reserved.

-0-